Update on the USFDA cGMP inspection at the Company’s formulations manufacturing facility (FTO-3) in Bachupally, Hyderabad: The Company has received the Establishment Inspection Report (EIR) and the USFDA has classified the inspection as Voluntary Action Indicated (VAI) and concluded that the inspection is closed under 21 CFR 20.64(d)(3).